Homepage > Company > Media > Pharma News > 2022 > British Pharma Industry Cites Six Companies for Code Violations

British Pharma Industry Cites Six Companies for Code Violations

The Association of the British Pharmaceutical Industry (ABPI) has cited six companies — Novo Nordisk, Daiichi-Sankyo, Lundbeck, AstraZeneca, UCB and Biogen — for breaching its self-regulated code of practice.

The harshest criticism was for Novo Nordisk for several violations including offering individual health professionals an inducement to prescribe products. The board publicly reprimanded the company which will now undergo an audit.

AstraZeneca was tagged for several violations including failing to certify promotional material and promoting an unlicensed indication, while Lundbeck was cited for promoting a medicine before it received marketing authorization.

December 14, 2022

https://www.fdanews.com/

Read also

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.